Clinical

Latest News


Latest Videos


CME Content


More News

With the explosion of new therapies in cancer care, the risk of each new therapy must be clearly understood prior to making treatment decisions with patients. Data from clinical trials alone are insufficient to educate these treatment choices, and real-world evidence from higher-risk populations should be generated to inform these treatment decisions.

The results of an ongoing study, presented at the annual meeting of the Heart Failure Association of the European Society of Cardiology in Seville, Spain, identified a 5-fold increased risk of death in heart failure patients who were depressed.

Encouraging results with a shorter course of hepatitis C treatment were presented at the Digestive Disease Week meeting. Patients receiving an 8-week course of sofosbuvir and daclatasvir, previously naïve to direct-acting antiviral treatment, achieved a sustained response at 12 weeks.

Authors led by Harvard's Frank Hu, MD, write that combating diabetes worldwide requires policy solutions that recognize the societal and environmental forces that work against those who might try to pursue healthier lifestyles. Hu recently spoke at Patient-Centered Diabetes Care 2015, presented by The American Journal of Managed Care and Joslin Diabetes Center.

Researchers at Cancer Research UK have challenged the current standard of care in advanced ovarian cancer patients. Results of their study, published in Lancet, found that administering chemotherapy prior to surgery can have huge benefits on health outcomes and the patient's quality of life.

A secondary analysis on results of the CAPTION trial pointed to a role for pharmacists in helping tailor the treatment regimen for patients with hypertension, although it did not improve blood pressure control.

A Science study found that recurrent mutations in the promoter of the telomerase gene, TERT, could be responsible for overexpression of telomerase in a majority of cancers, thereby sustaining the replicative potential of cancer cells.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo